title: A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
abstract: OBJECTIVE
  The aim of this study was to systematically review the literature on the influence of oxaliplatin administration (e.g. cumulative dose, dose intensity, number of cycles and combination regimen) on the long-term prevalence of oxaliplatin-induced peripheral neuropathy (O-IPN) at least 12 months after termination of chemotherapy.
  
  
  METHODS
  A computerized search of literature on databases PubMed and Cochrane was performed. Published original articles were included if they reported about long-term O-IPN and gave concomitant information about oxaliplatin therapy given to the patients. All articles were assessed for quality.
  
  
  RESULTS
  We included 14 articles (n=3,869 patients), and the majority of these studies were of high quality. All included patients who were treated for colorectal cancer, mainly with oxaliplatin in combination with 5-fluorouracil/leucovorin. Median cumulative doses and dose intensity varied between 676 and 1,449 mg/m2 and 30.8 and 42.6 mg/m2/week, respectively. Neuropathy assessment differed between studies, and the National Cancer Institute-Common Terminology Criteria (NCI-CTC) was used most often. The degree of neuropathy ranged from grade 0 to 3. Only six studies directly assessed the relationship between oxaliplatin administration and neuropathy. Of these studies, five did find a relation between neuropathy and higher cumulative dose, while one study did not find a relation.
  
  
  CONCLUSIONS
  O-IPN is still present in a great amount of patients in ≥12 months after termination of therapy. A higher cumulative dose is likely to have an influence on the development of long-term O-IPN. More studies are needed that assess long-term neuropathy and oxaliplatin administration by means of validated neuropathy assessments.
authors.affiliation: Department of Internal Medicine, Máxima Medical Centre, PO Box 7777, 5500 MB, Veldhoven, The Netherlands.
authors.forename: A J M
authors.initials: AJ
authors.lastname: Beijers
authors.forename: F
authors.initials: F
authors.lastname: Mols
authors.forename: G
authors.initials: G
authors.lastname: Vreugdenhil
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D016032:Randomized Controlled Trials as Topic
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil
references.citation: J Clin Oncol. 2000 Aug;18(16):2938-47
references.pmid: 10944126
references.citation: PLoS One. 2011 Apr 08;6(4):e18469
references.pmid: 21494615
references.citation: Ann Oncol. 2010 Aug;21(8):1657-1661
references.pmid: 20089559
references.citation: Ann Neurol. 2012 Jan;71(1):26-39
references.pmid: 21698661
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3385-90
references.pmid: 19414665
references.citation: Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19444-9
references.pmid: 23115331
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2198-204
references.pmid: 17470851
references.citation: Eur J Cancer. 2005 Nov;41(17):2613-9
references.pmid: 16226458
references.citation: J Clin Oncol. 2011 Oct 1;29(28):3768-74
references.pmid: 21859995
references.citation: Chemotherapy. 2008;54(5):395-403
references.pmid: 18781065
references.citation: J Clin Oncol. 2011 Apr 10;29(11):1465-71
references.pmid: 21383294
references.citation: Eur J Cancer. 2001 Dec;37(18):2457-63
references.pmid: 11720843
references.citation: Muscle Nerve. 2005 Jul;32(1):51-60
references.pmid: 15880395
references.citation: Acta Oncol. 2009;48(6):832-41
references.pmid: 19308757
references.citation: Oncologist. 2011;16(5):708-16
references.pmid: 21478275
references.citation: Semin Oncol. 2003 Aug;30(4 Suppl 15):5-13
references.pmid: 14523789
references.citation: Support Care Cancer. 2004 Sep;12(9):619-25
references.pmid: 15258838
references.citation: Epidemiology. 2007 Nov;18(6):805-35
references.pmid: 18049195
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2205-11
references.pmid: 17470850
references.citation: Clin Colorectal Cancer. 2012 Jun;11(2):93-100
references.pmid: 22154408
references.citation: Neth J Med. 2012 Jan;70(1):18-25
references.pmid: 22271810
references.citation: Ann Oncol. 2012 Dec;23(12):3116-3122
references.pmid: 22865779
references.citation: J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):392-8
references.pmid: 23813745
references.citation: J Neurol. 2002 Jan;249(1):9-17
references.pmid: 11954874
references.citation: Cancer. 2013 Oct 1;119(19):3570-7
references.pmid: 23821303
references.citation: Ann Oncol. 1998 Jul;9(7):739-44
references.pmid: 9739440
references.citation: Cancer. 2012 Nov 15;118(22):5614-22
references.pmid: 22569841
references.citation: J Clin Oncol. 2013 Jul 20;31(21):2699-707
references.pmid: 23775951
references.citation: N Engl J Med. 2004 Jun 3;350(23):2343-51
references.pmid: 15175436
references.citation: J Clin Oncol. 2003 Jun 1;21(11):2059-69
references.pmid: 12775730
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3109-16
references.pmid: 19451431
references.citation: Int J Cancer. 2011 Feb 1;128(3):682-90
references.pmid: 20473862
references.citation: Support Care Cancer. 2014 Feb;22(2):513-8
references.pmid: 24122404
references.citation: Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68
references.pmid: 16806962
references.citation: Cancer Chemother Pharmacol. 2008 Jan;61(1):105-11
references.pmid: 17429632
references.citation: Eur Neurol. 2006;56(1):13-6
references.pmid: 16825773
references.citation: Support Care Cancer. 2013 Dec;21(12):3307-13
references.pmid: 23903798